Aims
There is little information about transmembrane protein 35B (TMEM35B) expression in glioma, and its functions in glioma remains no clue. Patients &
Conclusions
TMEM35B expression is upregulated in gliomas, and its knockdown hinders tumor progression, highlighting the protein as a potential biomarker for glioma diagnosis.
Methods
Immunohistochemistry was used to measure TMEM35B expression levels and CCK8 and Transwell assays were analyzed the proliferative and migratory and invasive.
Results
TMEM35B protein was significantly higher in gliomas and correlated with a higher tumor TNM stages. Receiver operating characteristic curve analysis revealed that TMEM35B had high diagnostic value in distinguishing among glioma, normal tissues, tumor stages III+IV, and I+II. Additionally, TMEM35B knockdown inhibited the proliferative, migratory, and invasive capacities of glioma cells. Conclusions: TMEM35B expression is upregulated in gliomas, and its knockdown hinders tumor progression, highlighting the protein as a potential biomarker for glioma diagnosis.